AstraZeneca hit $ 6.9 billion Deal with Daiichi Sankyo

He added: "The agreement is well structured, in our opinion reflecting the different levels of risk amounts. . "

AstraZeneca's prospects depend greatly on its pipeline products and new product launches. J.P .. Morgan Cazenove equity research analyst James Gordon notes: "All in all, we see the Daiichi asset as a great potential … But we are more mixed on the equity increase."

Over the next 12 months, Gordon expects to see further rating of Astra shares as the market's confidence in Astra's strong long-term growth outlook is rising.

As the analyst called to exclude any equity-funded acquisitions, the management was characterized by the equity increase as "exceptional" and noted that it reflects the "extraordinary" nature of that asset. They confirmed that they do not intend to raise equity on a regular basis.

There have been a number of healthcare companies operating the M&A merger. During the last year bindings have arisen between, among other things. Bristol-Myers Squibb and Celgene, Shire and Takeda, Roche and Spark Therapeutics.

Pharma companies across the globe are competing to replace old drugs by paying tight premiums for access to more specialized treatments.

AstraZeneca, as the broad industry, is shifting away from a more primary care portfolio to one that is more oncologically focused. The Daichii Sankyo cooperation requires no shareholder or legal approval.

AstraZeneca expects the transaction to have a neutral financial impact in 201

9, which increases core earnings per share. Shares from 2020 and then contributes significantly in 2023. The company has confirmed 2019 financial guidance. [19659002] Daichii Sankyo shares climbed the news, while AstraZeneca's shares fell in early trading Friday.